Dornase Alfa
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Dornase Alfa
Dornase Alfa: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Dornase Alfa, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| cystic fibrosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 5704F | Pulmozyme | Solution for inhalation 2.5 mg (2,500 un | Valid |
Safety Considerations
- Drug Interactions: One moderate-level interaction is recorded, with inhaled rapid-acting human insulin (source: DDInter).
No warning or contraindication text was available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.